Vaccine (DNA plasmid) · Immune activation, directed at telomerase reverse transcriptase (TERT) · developed by INOVIO PHARMACEUTICALS
INO-1401 is a DNA vaccine encoding a synthetic consensus sequence of telomerase reverse transcriptase (TERT) with immunogenic mutations. Administered intramuscularly with electroporation, it activates cytotoxic T-cell responses against telomerase-expressing tumor cells. It is studied in multiple solid tumors including breast, lung, pancreatic, head and neck, ovarian, colorectal, gastric, esophageal, and hepatocellular cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02960594 | Phase 1 | Breast Cancer | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerColoRectal CancerEsophageal CancerGastric CancerHead and Neck CancerHepatoCellular CarcinomaLung CancerOvarian CancerPancreatic Cancer
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →